Market Cap$160.13B

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
AMGEN Inc.AMGEN Inc.42.62.87%75%5.612.7

Earnings Call Q4 2023

February 6, 2024 - AI Summary

Amgen reported strong performance in 2023, with double-digit volume growth in all four quarters and record sales for 18 of its medicines.
The acquisition of Horizon Therapeutics has added a significant rare disease business to Amgen's portfolio, positioning it for long-term growth.
Promising pipeline milestones are expected in 2024, including Phase II data for the lead obesity molecule MariTide and Phase III data for several other assets.

Exclusive for Stockcircle Pro members

Sign upSign Up

Target Price by Analysts

3.7% upsideAMGEN Target Price DetailsTarget Price

Current Fair Value

71% upside

Undervalued by 71% based on the discounted cash flow analysis.

Share Statistics

Market cap$160.13 Billion
Enterprise Value$214.44 Billion
Dividend Yield$8.5715 (2.87%)
Earnings per Share$7.0
Outstanding Shares536,434,692
Avg 30 Day Volume2,208,563


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio42.55
Price to Sales5.56
Price to Book Ratio34.0
Enterprise Value to Revenue7.26
Enterprise Value to EBIT30.78
Enterprise Value to Net Income56
Total Debt to Enterprise0.3
Debt to Equity12.75

Revenue Sources

No data

Insider Trades

ESG Score

No data

About AMGEN Inc.

22,000 employees
CEO: Robert Bradway

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advan...